Oculis Holding AG (OCS), a clinical-stage biopharmaceutical company, on Monday reported its first-quarter financial results and provided pipeline highlights.
The company specializes in developing therapies for treating ophthalmic, neuro-ophthalmic, and neurological diseases.
Cash, cash equivalents, and marketable securities held by the company on March 31, 2026, amounted to CHF 222 million.
Pipeline Highlights:
OCS-01 is being developed for the treatment of diabetic macular edema (DMD). The DIAMOND program consists of two Phase 3 trials evaluating OCS-01 formulated as eye drops and administered to DME patients over 52 weeks. Topline results are expected by June 2026, and a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) is planned for Q4 2026.
Licaminlimab is an investigational anti-TNFa monoclonal antibody developed for the treatment of dry eye disease (DED). The Phase 3 PREDICT-1 trial for licaminlimab in treating DED is expected to yield topline results by the end of this year.
Privosegtor is a novel peptoid small molecule developed for the treatment of optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). The drug is the only neuroprotective therapy developed for potentially treating ON, and previously received a Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and a Breakthrough therapy designation from the FDA.
The company received a special protocol assessment (SPA) agreement from the FDA for the PIONEER program to assess privosegtor in treating ON and NAION across two Phase 3 trials, PIONEER-1 and PIONEER-2. The agreement validated the clinical trial design for the PIONEER program and provided a pathway to facilitate an NDA submission.
OCS closed Monday at $32.65, up 0.03%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.